Which antifungal agents is Candida glabrata susceptible to?

Candida glabrata Antifungal Susceptibility

Candida glabrata is most reliably sensitive to echinocandins (caspofungin, micafungin, anidulafungin), with >95-99% susceptibility rates, making them the first-line treatment choice. 1

Primary Susceptibility Profile

Echinocandins (First-Line)

• Highest and most consistent susceptibility across all antifungal classes
• Caspofungin, micafungin, and anidulafungin show 95-100% susceptibility 2, 3, 4
• The IDSA 2016 guidelines strongly recommend echinocandins as initial therapy for C. glabrata infections 1
• Resistance remains rare at approximately 2-3% 2, 4

Amphotericin B (Alternative)

• Excellent activity with 96-99% susceptibility 3, 5, 4
• Lipid formulations (3-5 mg/kg daily) recommended as reasonable alternative when echinocandins cannot be used 1
• Particularly important for azole- and echinocandin-resistant infections 1

5-Flucytosine

• Very high susceptibility at 99% 5, 4
• Typically used in combination therapy rather than monotherapy

Problematic Susceptibility: Azoles

Fluconazole - Major Concern

C. glabrata exhibits intrinsically reduced susceptibility to fluconazole, which has worsened over time:

• Only 19-63% fully susceptible 6, 5
• Dose-dependent susceptibility (SDD) now predominates: increased from 27% (1999-2001) to 75% (2007) 6
• Approximately 14% show frank resistance 4
• The guidelines specify that higher-dose fluconazole (800 mg daily) should only be used for C. glabrata if susceptibility testing confirms susceptibility 1

Voriconazole

• Better than fluconazole with 93% susceptibility 5
• Can be considered for susceptible isolates at 200-300 mg twice daily 1
• Cross-resistance with fluconazole occurs in approximately 11.6% of isolates 4

Posaconazole and Itraconazole

• Limited specific data for C. glabrata in guidelines
• Generally better activity than fluconazole but not first-line options

Critical Clinical Guidance

Susceptibility testing is mandatory - The IDSA guidelines strongly recommend testing for azole susceptibility on all C. glabrata isolates, and echinocandin susceptibility testing should be considered in patients with prior echinocandin exposure 1.

Treatment Algorithm for C. glabrata:

1. Initial therapy: Start with an echinocandin (strong recommendation) 1

   • Caspofungin: 70 mg loading, then 50 mg daily
   • Micafungin: 100 mg daily
   • Anidulafungin: 200 mg loading, then 100 mg daily

2. Step-down therapy: Only transition to azoles if:

   • Patient is clinically stable
   • Susceptibility testing confirms susceptibility
   • Use high-dose fluconazole (800 mg daily) or voriconazole (200-300 mg twice daily) 1

3. Resistant infections: Use lipid formulation amphotericin B (3-5 mg/kg daily) for suspected azole- and echinocandin-resistant cases 1

Common Pitfalls

• Never assume fluconazole susceptibility - C. glabrata has intrinsically reduced azole susceptibility that continues to worsen 6, 7
• Don't use standard-dose fluconazole - If azoles must be used, only high-dose fluconazole (800 mg) is appropriate for documented susceptible isolates 1
• Avoid empiric azole monotherapy - Start with echinocandins while awaiting susceptibility results 1
• Recent echinocandin exposure matters - Consider resistance testing if prior echinocandin use, as this is a risk factor for resistance 1

The shift toward dose-dependent susceptibility and resistance to fluconazole represents a concerning epidemiological trend that reinforces the guideline recommendation for echinocandins as first-line therapy 6, 7.